Advanced search
Publication Cover
ClinicoEconomics and Outcomes Research Volume 9, 2017 - Issue
Submit an article Journal homepage
76
Views
9
CrossRef citations to date
0
Altmetric
Original Research

Evaluating the cost-effectiveness of afatinib after platinum-based therapy for the treatment of squamous non-small-cell lung cancer in France

Maud Pignata1 HEVA-HEOR, LyonCorrespondence[email protected]
,
Christos Chouaid2 Centre Hospitalier, Intercommunal de Créteil, Créteil
,
Katell Le Lay3 Boehringer Ingelheim, Paris, France
,
Laura Luciani3 Boehringer Ingelheim, Paris, France
,
Ceilidh McConnachie4 Ossian Health Economics and Communications, Basel, Switzerland
,
James Gordon5 Boehringer Ingelheim, GmbH, Germany
&
Stéphane Roze1 HEVA-HEOR, Lyon
 show all
Pages 655-668 | Published online: 25 Oct 2017

Citations (9)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (2)

Joo-Young Byun, Sun-Kyeong Park, Boon Peng Ng, Yi-Shao Liu, Chae-Rin Kim & Chanhyun Park. (2022) A systematic review of economic evaluations of tyrosine kinase inhibitors for non-small cell lung cancer (NSCLC). Expert Opinion on Pharmacotherapy 23:11, pages 1247-1257.
Read now
Edgardo S Santos & Lowell Hart. (2020) Advanced Squamous Cell Carcinoma of the Lung: Current Treatment Approaches and the Role of Afatinib. OncoTargets and Therapy 13, pages 9305-9321.
Read now

Articles from other publishers (7)

Masnoon Saiyed, Joshua Byrnes, Tushar Srivastava, Paul Scuffham & Martin Downes. (2020) Cost-Effectiveness of Lenvatinib Compared with Sorafenib for the First-Line Treatment of Advanced Hepatocellular Carcinoma in Australia. Clinical Drug Investigation 40:12, pages 1167-1176.
Crossref
John J. Kim, Thomas McFarlane, Stephen Tully & William W.L. Wong. (2020) Lenvatinib Versus Sorafenib as First-Line Treatment of Unresectable Hepatocellular Carcinoma: A Cost–Utility Analysis. The Oncologist 25:3, pages e512-e519.
Crossref
Iluminada Fuertes-Fuertes, J. David Cabedo & Inmaculada Jimeno-García. (2019) Capturing the Invisible Wealth in Nonprofits to Overcome Myopic Perceptions. Sustainability 12:1, pages 48.
Crossref
Daniel Gallacher, Peter Auguste, Pamela Royle, Hema Mistry & Xavier Armoiry. (2019) A Systematic Review of Economic Evaluations Assessing the Cost-Effectiveness of Licensed Drugs Used for Previously Treated Epidermal Growth Factor Receptor (EGFR) and Anaplastic Lymphoma Kinase (ALK) Negative Advanced/Metastatic Non-Small Cell Lung Cancer. Clinical Drug Investigation 39:12, pages 1153-1174.
Crossref
Ajaikumar B Kunnumakkara, Devivasha Bordoloi, Bethsebie Lalduhsaki Sailo, Nand Kishor Roy, Krishan Kumar Thakur, Kishore Banik, Mehdi Shakibaei, Subash C Gupta & Bharat B Aggarwal. (2019) Cancer drug development: The missing links. Experimental Biology and Medicine 244:8, pages 663-689.
Crossref
Jun Zhu, Wei He, Ming Ye, Jie Fu, Yun-Bo Chu, Yi-Yang Zhao, Yan-Jun Zhang, David Kuo & Bin Wu. (2018) Cost–effectiveness of afatinib and erlotinib as second-line treatments for advanced squamous cell carcinoma of the lung. Future Oncology 14:27, pages 2833-2840.
Crossref
. (2017) Afatinib cost effective for advanced squamous NSCLC. PharmacoEconomics & Outcomes News 791:1, pages 10-10.
Crossref

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.